| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
7β-Hydroxycholesterol does not have a specific therapeutic target but functions as a potent inducer of oxidative stress and a cytotoxic oxysterol. It induces apoptosis and cell death in various cell types, including human umbilical vein endothelial cells (HUVECs), monocytes, smooth muscle cells, and endothelial cells. The compound's mechanism of action involves the induction of organelle dysfunction (mitochondria, lysosomes, and peroxisomes) that leads to cell death.
|
|---|---|
| ln Vitro |
7β-Hydroxycholesterol is a powerful inducer of oxidative stress that induces dysfunction of organelles (mitochondria, lysosomes, and peroxisomes) that can cause cell death. It induces apoptosis and cell death of human umbilical vein endothelial cells (HUVECs) in vitro in a concentration-dependent manner. The compound is cytotoxic to monocytes, smooth muscle cells, and endothelial cells. As a primary oxysterol found in LDL, it may contribute to the pathogenesis of atherosclerosis.
|
| ln Vivo |
In vivo, 7β-hydroxycholesterol is an oxysterol formed by cholesterol oxidation that may contribute to the pathogenesis of atherosclerosis and other oxidative stress-related diseases. As a cytotoxic compound, it induces cell death in various cell types. The compound is not used as a therapeutic agent but is studied for its role in disease pathogenesis. Specific in vivo efficacy studies are not applicable, as the compound is a pathogenic metabolite rather than a drug.
|
| Enzyme Assay |
In vitro cytotoxicity assays for 7β-hydroxycholesterol typically involve treating various cell types (such as HUVECs, monocytes, or smooth muscle cells) with the compound at concentrations ranging from 1 to 100 μM for 24-72 hours. Cell viability is assessed using MTT, LDH release, or trypan blue exclusion assays. Apoptosis is assessed by measuring caspase activity, Annexin V staining, or DNA fragmentation. Oxidative stress is measured using fluorescent probes such as DCFH-DA. The compound is dissolved in ethanol or DMSO and diluted in cell culture medium.
|
| Cell Assay |
In vitro cellular assays for 7β-hydroxycholesterol typically involve treating cultured cells (such as HUVECs, macrophages, or smooth muscle cells) with the compound at concentrations ranging from 1 to 100 μM for 24-72 hours. Cell viability is assessed using MTT or resazurin reduction assays. Apoptosis is assessed by Annexin V/PI staining or caspase activity assays. Organelle dysfunction is assessed by measuring mitochondrial membrane potential (using JC-1 dye), lysosomal integrity (using acridine orange), and peroxisomal function. The compound is dissolved in ethanol or DMSO and diluted in cell culture medium.
|
| Animal Protocol |
In vivo animal studies for 7β-hydroxycholesterol are not typically performed for therapeutic purposes, as the compound is a cytotoxic oxysterol rather than a therapeutic agent. The compound may be administered to animals to study its role in atherosclerosis or other oxidative stress-related diseases. Tissue samples are collected for histological and biochemical analysis. The compound is not intended for human therapeutic use.
|
| ADME/Pharmacokinetics |
7β-Hydroxycholesterol has a molecular weight of 402.65 g/mol and formula C27H46O2. It is an oxysterol derived from cholesterol oxidation. The compound is typically stored at -20°C. It is soluble in organic solvents such as ethanol, DMSO, and chloroform. Detailed PK parameters are not applicable for this compound, as it is not used as a therapeutic agent. The compound is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
7β-Hydroxycholesterol is a cytotoxic compound that induces cell death and oxidative stress. The compound is intended for research use only and is not approved for human therapeutic applications. Appropriate safety precautions should be taken when handling, including wearing gloves and protective eyewear. The compound should not be inhaled, swallowed, or allowed to contact skin and eyes. Standard toxicity assessments would include acute toxicity and cytotoxicity studies.
|
| References | |
| Additional Infomation |
7β-hydroxycholesterol is an oxosterol and 7β-hydroxy steroid whose function is related to cholesterol. It has been reported in Heteroxenia ghardaqensis, Bombyx mori, and other organisms with relevant data.
7β-Hydroxycholesterol (CAS 566-27-8) is an oxysterol formed by enzymatic and non-enzymatic oxidation of cholesterol. It has a molecular weight of 402.65 g/mol and formula C27H46O2. The compound is a powerful inducer of oxidative stress that induces organelle dysfunction and cell death. It induces apoptosis of HUVECs in a concentration-dependent manner. 7β-Hydroxycholesterol is the primary oxysterol found in LDL. It is not approved for clinical use. |
| Molecular Formula |
C27H46O2
|
|---|---|
| Molecular Weight |
402.65294
|
| Exact Mass |
402.349
|
| CAS # |
566-27-8
|
| Related CAS # |
7ß-Hydroxycholesterol-d7;349553-97-5
|
| PubChem CID |
473141
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
515.3±38.0 °C at 760 mmHg
|
| Melting Point |
165-167ºC
|
| Flash Point |
214.7±21.4 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.536
|
| LogP |
7.94
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
624
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C
|
| InChi Key |
OYXZMSRRJOYLLO-KGZHIOMZSA-N
|
| InChi Code |
InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-25,28-29H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,24+,25+,26+,27-/m1/s1
|
| Chemical Name |
(3S,7R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~248.35 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4835 mL | 12.4177 mL | 24.8355 mL | |
| 5 mM | 0.4967 mL | 2.4835 mL | 4.9671 mL | |
| 10 mM | 0.2484 mL | 1.2418 mL | 2.4835 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
